{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:12:00Z","timestamp":1790860320278,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.10.001","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"331-341","source":"Crossref","is-referenced-by-count":51,"title":["Response definitions and European Leukemianet Management recommendations"],"prefix":"10.1016","volume":"22","author":[{"given":"Michele","family":"Baccarani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.10.001_bib1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.10.001_bib2","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular response to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.10.001_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib4","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","article-title":"Current and emerging treatment options in chronic myeloid leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.10.001_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Baccarani M on behalf of the European LeukemiaNet. Chronic myeloid leukemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.10.001_bib6","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.10.001_bib8","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic response in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib9","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib10","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.001_bib12","first-page":"1","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib \u2013resistant and intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.10.001_bib13","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.10.001_bib14","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is a active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"Le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib16","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-07-5015","article-title":"Nilotinib","volume":"14","author":"Deininger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2009.10.001_bib17","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white bone marrow cells in CML patients treated with imatinib","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.001_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0609.2004.00287.x","article-title":"Assessment of the response to imatinib in chronic myeloid leukemia patients: comparison between the FISH, multiplex and RT-PCR methods","volume":"73","author":"Raanani","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2009.10.001_bib19","unstructured":"Testoni N, Marzocchi G, Luatti S, et\u00a0al. A prospective study in Ph+ chronic myeloid leukemia (CML) patients showing that interphase fluorescence-in-situ- hybridization (I-FISH) is effective as conventional cytogenetics for definition of cytogenetic response to imatinib. Correlation with molecular response (a GIMEMA CML WP study). Haematologica. in press."},{"key":"10.1016\/j.beha.2009.10.001_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/sj.leu.2404716","article-title":"Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements","volume":"21","author":"Saldanha","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.001_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of a BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.001_bib23","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","article-title":"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia","volume":"11","author":"Jones","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.beha.2009.10.001_bib25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib26","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.10.001_bib27","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"De Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.10.001_bib28","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, et\u00a0al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, in press."},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V112.11.76.76","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib30","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib31","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alfa plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V112.11.129.129","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib33","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V112.11.333.333","article-title":"Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia \u2013 an interim analysis of the randomized German CML study IV","volume":"112","author":"M\u00fcller","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.V112.11.2113.2113","article-title":"Long term follow up of patients with CML in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2009.10.001_bib36","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.beha.2009.10.001_bib37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood.V112.11.445.445","article-title":"Significance of rising levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in complete cytogenetic response (CGCR)","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib39","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2009.10.001_bib40","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(07)70379-0","article-title":"Part II: management of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2009.10.001_bib41","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of BCR-ABL1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib42","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib43","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2009.10.001_bib44","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.001_bib45","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.10.001_bib46","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.10.001_bib47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib48","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2009.10.001_bib49","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable response in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib50","unstructured":"Cortes I, Kantarjian H, Goldberg S, et\u00a0al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol, in press."},{"key":"10.1016\/j.beha.2009.10.001_bib51","unstructured":"Castagnetti F, Palandri F, Amabile M, et\u00a0al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase II trial of the Gimema CML WP. Blood, in press."},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.V112.11.130.130","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib53","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukemia. A European LeukemiaNet study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib54","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V112.11.183.183","article-title":"Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML Group (FI LMC)","volume":"112","author":"Guilhot","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V112.11.184.184","article-title":"Randomized comparison of imatinib 400 mg vs. imatinib + IFN vs. imatinib + araC vs. imatinib after IFN vs. imatinib 800 mg: optimized treatment and survival. Designed first interim analysis of the German CML study IV","volume":"112","author":"Hehlmann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib56","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance","volume":"102","author":"Burgess","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.beha.2009.10.001_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1016\/j.beha.2009.10.001_bib58","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.beha.2009.10.001_bib59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.10.001_bib60","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutation","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib61","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/blood.V112.11.450.450","article-title":"Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"112","author":"Baccarani","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib62","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood.V112.11.1095.1095","article-title":"Dasatinib-associated major molecular responses are rapidly achieved in patients with chronic myeloid leukemia in chronic phase (CML-CP) following resistance, suboptimal response, or intolerance on imatinib","volume":"112","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib63","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.V112.11.3224.3224","article-title":"Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with accelerated phase chronic myeloid leukemia (CML-AP): 2-year follow-up data from CA180-035","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib64","unstructured":"Hochhaus A, M\u00fcller MC, Radich J, et\u00a0al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia, in press."},{"key":"10.1016\/j.beha.2009.10.001_bib65","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib66","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V112.11.332.332","article-title":"Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival","volume":"112","author":"Milojkovic","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell."},{"key":"10.1016\/j.beha.2009.10.001_bib68","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several BCR-ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib69","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell."},{"key":"10.1016\/j.beha.2009.10.001_bib70","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity oof BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistance ABL kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1016\/j.beha.2009.10.001_bib71","first-page":"3","article-title":"Advances in the structural biology, design and clinical development of BCR-ABL kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biophys Acta"},{"key":"10.1016\/j.beha.2009.10.001_bib72","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib73","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","article-title":"Indentification of BCR-ABL point mutations conferring resistance to the ABL kinase inhibitor AMN107 (nilotinib) by random mutagenesis study","volume":"109","author":"Ray","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib74","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.10.001_bib75","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients whith chronic myeloid leukaemia before allogeneic blood or marrow transplantation: cronic leukemia working party of the European group for blood and marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2009.10.001_bib76","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2009.10.001_bib77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.V112.11.448.448","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: high survival rate following allogeneic HSCT after imatinib failure: results of the German CML study IV","volume":"112","author":"Saussele","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.001_bib78","unstructured":"Baccarani M, Cortes J, Pane F, et\u00a0al. Chronic myeloid leukemia. An update of concepts and management recommendations of European Leukemianet. J Clin Oncol., in press."},{"key":"10.1016\/j.beha.2009.10.001_bib79","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"92","author":"Baccarani","year":"2008","journal-title":"Haematologica"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:59:31Z","timestamp":1590281971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000711"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.10.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}